StockData

Health In Tech vs Roadzen

HIT and RDZN side by side, both in insurance agents, brokers, and service. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HIT and RDZN compare

Roadzen is the larger company, worth 2.6 times as much as Health In Tech ($96.2M against $36.7M).

Roadzen grew revenue faster over the last twelve months (30.5% versus 23.0% for Health In Tech).

Health In Tech keeps more of each dollar of sales as profit, with a net margin of −12.0% compared with −46.9% at Roadzen.

Health In Tech scores higher on the StockData Score (3 against 2 for Roadzen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHITRDZN
Size and price
Market cap$36.7M$96.2M
Share price$0.559$1.13
Change, 1 year−80.8%−25.2%
Beta (5Y)1.450.81
Employees87458
StockData Score
Total score3 (better)2
Valuation score11
Growth score11
Performance score00
Health score1 (better)0
Dividend score00
Valuation
P/S1.1× (better)1.6×
Growth
Revenue growth (TTM)23.0%30.5% (better)
Net income growth (TTM)−390%–
EPS growth (TTM)−333%–
Profitability
Gross margin53.9%60.7% (better)
Operating margin–−21.6%
Net margin−12.0% (better)−46.9%
Return on equity−24.0%–
Financial health
Current ratio2.18 (better)0.45
Altman Z-score3.84 (better)−7.23
Piotroski F-score6 (better)5
Dividends and buybacks
Buyback yield–−13.1%
Shareholder yield0.00% (better)−13.1%
Ownership
Held by institutions7.1%–
Held by insiders76.6%23.8%
Insider net buying, 12 months−$40.6K$43.2K (better)
Short interest, % of float3.9%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.